LONDON, ONTARIO--(Marketwire - Nov. 1, 2011) -Critical Outcome Technologies Inc. (COTI) (TSX VENTURE:COT), a predictive Artificial Intelligence technology company specializing in accelerating the discovery of small molecules, announced today that Dr. Wayne Danter, COTI's CEO and CSO, will be delivering a podium presentation on Wednesday, November 2, 2011 at 2:55pm Eastern time at Discovery on Target: Emerging Targets for the Kinase Inhibitor Pipeline held at the Park Plaza Hotel and Towers in Boston, MA. The presentation is entitled COTI-2: A highly effective and selective modulator of AKT/AKT2 protein levels and phospho-activation for the treatment of susceptible human cancers.

This presentation will highlight the scientific results from recent pharmacodynamic and pharmacokinetic experiments, which demonstrate COTI-2's ability to significantly inhibit the growth of cancer cells that over express AKT/AKT2, confirming it as a targeted therapy candidate. "This upcoming presentation affords us the opportunity to share our insights into the potential for COTI-2 with a targeted scientific audience of key influencers from many partnering organizations," said Dr. Danter. "I am delighted to have the opportunity to share with this audience the exciting results of our most recent experiments, highlighting the potential of COTI-2 as a highly selective and well tolerated targeted oncology therapy candidate."

COTI-2's specific cellular targeting, low toxicity, and proven efficacy support a potentially dramatic change in the treatment of cancers that over express AKT/AKT2. Over expression of AKT/AKT2 is common in a broad range of human cancers, including ovarian, endometrial, pancreatic, breast, colorectal and lung. The percent of tumors producing excess active AKT/AKT2 ranges from 20 to 100%, depending on the cancer type. COTI-2 is the most advanced compound in COTI's pipeline discovered through CHEMSAS®, a proprietary artificial intelligence platform.

About Critical Outcome Technologies Inc. (COTI)

COTI is a leading-edge company specializing in accelerating the discovery of small molecules thus enabling these new drugs to be brought to market in a more cost effective, efficient and timely manner. COTI'S proprietary Artificial Intelligence platform, CHEMSAS®, utilizes a series of predictive computer models to identify compounds most likely to be successfully incorporated in disease-specific drug discovery, as well as subsequent optimization and preclinical development. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective. Upon confirming the predictions of CHEMSAS® through a series of preclinical tests, COTI seeks to license these compounds for further preclinical and clinical development.

Contributing Sources

---

Market Wire